£106.21

Springer Squamous cell Carcinoma: Molecular Therapeutic Targets

Price data last checked 12 day(s) ago - will refresh soon

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

This is the usual price. Wait for it to drop, or tell us your number.

£106 today · usual range £87–£109 · best ever £87

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey
↓ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 79 days · 79 data points (no recent data)

Historical
Generating forecast…
£108.75 £84.83 £90.05 £95.27 £100.49 £105.71 £110.93 27 April 2026 16 May 2026 05 June 2026 24 June 2026 14 July 2026

Price Distribution

Price distribution over 79 days • 5 price levels

Days at Price
Current Price
5 days 43 days 9 days · current 7 days · current 15 days 0 11 22 32 43 £87 £105 £106 £107 £109 Days at Price

Price Analysis

Most common price: £105 (43 days, 54.4%)

Price range: £87 - £109

Price levels: 5 different prices over 79 days

Description

This edited volume is about novel targeted therapies for the treatment of advanced neoplasms of the head and neck (HNSCC) with particular reference to oral squamous cell carcinomas and covers specific fields of cancer genetics and genomics for personalized medicine. The landmark studies from the HNSCC Cancer Genome Anatomy (TCGA) and the cancer Genome Atlas 2015 have revealed the multiplicity and diversity of genetic alterations in HNSCC. This remarkable body of information has elucidated novel druggable targets (eg. EGFR, mTOR, p53, survivin andaberrant microRNA) for therapeutic interventions in head and neck cancer. Readers will discover the importance of the biology and pathology of squamous cell carcinomas, the role of cancer stem cells and other factors that contribute to resistance to curative therapies such as hypoxia. We present an in-depth analysis of the HNSCC oncogenome describing the distinct molecular alterations in squamous cell carcinomas, which participate in specific molecular pathways whose dysregulation may contribute to most HNSCC cases. Final chapters of the book elucidate how these important cancer-driving molecular events and molecular pathways could be targeted to treat head and neck cancers and their therapeutic applications for targeted therapies based on clinical trials reported worldwide. This book is aimed at a broad audience, including scientists, physicians, surgeons, and post graduate students engaged in oncology and provide the readers with an up-to-date, interdisciplinary knowledge and tools to better understand the evolving areas of targeted gene therapy and the key concept of personalized medicine in head and neck cancer.

Product Specifications

Format
hardcover
Domain
Amazon UK
Release Date
04 April 2017
Listed Since
12 January 2017

Barcode

No barcode data available

Similar Products You Might Like

Improving the Therapeutic Ratio in Head and Neck Cancer (Volume 6) (Cancer Sensitizing Agents for Chemotherapy, Volume 6)
97% match

Improving the Therapeutic Ratio in Head and Neck Cancer (Volume 6) (Cancer Sensitizing Agents for Chemotherapy, Volume 6)

Academic Press

£112.58 10 Jul 2026
Oxford Textbook of Cancer Biology - Oxford University Press
97% match

Oxford Textbook of Cancer Biology - Oxford University Press

Oxford University Press

£138.10 25 Jul 2026
Head and Neck Cancer: Basic and Clinical Aspects: 74 (Cancer Treatment and Research, 74)
97% match

Head and Neck Cancer: Basic and Clinical Aspects: 74 (Cancer Treatment and Research, 74)

Springer

£165.81 13 Jul 2026
Manual of Clinical Oncology, Fourth Edition Fully Revised (UICC International Union Against Cancer)
97% match

Manual of Clinical Oncology, Fourth Edition Fully Revised (UICC International Union Against Cancer)

Springer

£89.99 06 Jul 2026
Head and Neck Cancer, An Issue of Hematology/Oncology Clinics of North America (Volume 35-5) (The Clinics: Internal Medicine, Volume 35-5)
97% match

Head and Neck Cancer, An Issue of Hematology/Oncology Clinics of North America (Volume 35-5) (The Clinics: Internal Medicine, Volume 35-5)

Elsevier

£72.20 03 Jul 2026
Demos Medical Head and Neck Cancers: Evidence-Based Treatment
96% match

Demos Medical Head and Neck Cancers: Evidence-Based Treatment

Demos Medical Publishing

£120.48 15 Jul 2026
Tumor Microenvironment: The Main Driver of Metabolic Adaptation: 1219 (Advances in Experimental Medicine and Biology, 1219)
96% match

Tumor Microenvironment: The Main Driver of Metabolic Adaptation: 1219 (Advances in Experimental Medicine and Biology, 1219)

Springer

£114.20 14 Jul 2026
Tumor Microenvironment: The Main Driver of Metabolic Adaptation: 1219 (Advances in Experimental Medicine and Biology, 1219)
96% match

Tumor Microenvironment: The Main Driver of Metabolic Adaptation: 1219 (Advances in Experimental Medicine and Biology, 1219)

Springer

£114.20 11 Jul 2026
Molecular Oncology: Underlying Mechanisms and Translational Advancements
96% match

Molecular Oncology: Underlying Mechanisms and Translational Advancements

Springer

£86.56 09 Jul 2026
Wiley-Blackwell Cancer Consult: Expertise for Clinical Practice
96% match

Wiley-Blackwell Cancer Consult: Expertise for Clinical Practice

Wiley-Blackwell

£118.26 15 Jul 2026
Oncogenes and Tumor Suppressor Genes in Human Malignancies: 63 (Cancer Treatment and Research, 63)
96% match

Oncogenes and Tumor Suppressor Genes in Human Malignancies: 63 (Cancer Treatment and Research, 63)

Springer

£149.64 10 Jul 2026
Advances in Cancer Research: 77: Volume 77
96% match

Advances in Cancer Research: 77: Volume 77

Academic Press

£90.49 08 Jul 2026